<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5941">
  <stage>Registered</stage>
  <submitdate>22/12/2015</submitdate>
  <approvaldate>22/12/2015</approvaldate>
  <nctid>NCT02675452</nctid>
  <trial_identification>
    <studytitle>AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma.</studytitle>
    <scientifictitle>A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2015-004777-32</secondaryid>
    <secondaryid>20150161</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Relapsed or Refractory Multiple Myeloma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AMG 176

Experimental: AMG 176 - Part 1a - Part 1a - dose exploration of the intervention, AMG 176

Other: AMG 176 - Part 1b - Part 1b dose exploration. The intervention is AMG 176

Other: AMG 176 - Part 2 - Part 2 Combination therapy The intervention is AMG 176


Treatment: drugs: AMG 176
Study Drug

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of adverse events and significant laboratory abnormalities</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Evaluate PK on different cohorts</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Determine the maximum tolerated dose (MTD)</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Determine the maximum tolerated combination (MTC)</outcome>
      <timepoint>6 months on treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Demonstrate investigational product inactivation of MCL-1</outcome>
      <timepoint>6 months on treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate preliminary efficacy according to the International Myeloma Working Group uniform response criteria</outcome>
      <timepoint>6 months on treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>INCLUSION CRITERIA: -Pathologically documented, multiple myeloma relapsed or refractory
        disease after at least 2 lines of therapy, -Must be willing and able to undergo bone marrow
        biopsy at screening, -Measurable disease per the IMWG response criteria, -Eastern
        Cooperative Oncology Group (ECOG) performance status of = 2, -Satisfactory hematological
        function without transfusion or growth factor support, -Subjects should not have received
        platelet transfusions for at least 1 week prior to screening, -Hemoglobin &gt; 8 g/dL,
        -Subjects may receive RBC transfusions or receive supportive care), -Other Inclusion
        Criteria May Apply.

        EXCLUSION CRITERIA: -Previously received an allogeneic stem cell transplant within 6 months
        OR having received immunosuppressive therapy within the last three months OR having signs
        or symptoms of acute or chronic graft-versus-host disease, -Autologous stem cell transplant
        less than 90 days prior to study day 1, -Multiple myeloma with IgM subtype, -POEMS
        syndrome, -Existing plasma cell leukemia, -Waldenstrom's macroglobulinemia, -Amyloidosis,
        -Glucocorticoid therapy (prednisone &gt; 30 mg/day or equivalent) within 7 days prior to
        starting treatment, -Topical or inhaled corticosteroids are permitted, -Infection requiring
        intravenous anti-infective treatments within 1 week of study enrollment (day 1), -Other
        exclusion Criteria May Apply.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Other</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>13/06/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>85</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/04/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Research Site - Parkville</hospital>
    <hospital>Research Site - Prahran</hospital>
    <postcode>3050 - Parkville</postcode>
    <postcode>3181 - Prahran</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>At least one dose level of AMG 176 will achieve acceptable safety and tolerability in
      subjects with relapsed or refractory multiple myeloma</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02675452</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Amgen Call Center</name>
      <address />
      <phone>866-572-6436</phone>
      <fax />
      <email>medinfo@amgen.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>